

Dated: February 4, 1997.  
 Barbara M. McGarey,  
*Deputy Director, Office of Technology Transfer.*  
 [FR Doc. 97-3528 Filed 2-12-97; 8:45 am]  
 BILLING CODE 4140-01-M

### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.  
**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESSES:** Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 232; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

The CCHC Zinc Fingers of the Retroviral Nucleocapsid Protein Comprises a New Target Useful in Identification and Evaluation of Anti-HIV Therapeutics

L Henderson, L Arthur, W Rice, and A Rein (NCI)  
 Serial No. 08/379,420 filed January 27, 1995

HIV-1 contains domains known as "CCHC zinc fingers" in the retroviral nucleocapsid (NC) protein. Nucleocapsid CCHC zinc fingers are highly conserved throughout nearly all retroviruses, and are sequences of 14 amino acids with four invariant residues, Cys(X)<sub>2</sub>Cys(X)<sub>4</sub>His(X)<sub>4</sub>Cys, that chelate zinc and perform essential functions in viral infectivity. HIV-1 NC has two CCHC zinc fingers, both of which are necessary for infectivity. Many compounds that disrupt the CCHC zinc fingers also inactivate HIV-1 by preventing the initiation of reverse transcription and by blocking production of infectious virus from previously infected cells by disruption of Gag processing. Compounds with this activity may be useful for developing

new types of antiretroviral drugs. The invention concerns antiretroviral compounds that disrupt the CCHC zinc fingers and assays for identifying such compounds. The invariant nature of retroviral zinc fingers extends the usefulness of these compounds to other retroviruses. Thus these assays are also useful for screening compounds effective against adult T cell leukemia, tropical spastic paraparesis caused by HTLV-1 and HTLV-II, feline leukemia virus, feline immunodeficiency virus, equine infectious virus, and lentivirus infections in other animals. This invention is available for licensing on an exclusive or non-exclusive basis.

(Portfolios: Infectious Diseases—Therapeutics, anti-virals, AIDS; Infectious Diseases—Research Materials)

Dated: February 4, 1997.

Barbara M. McGarey,  
*Deputy Director, Office of Technology Transfer.*  
 [FR Doc. 97-3529 Filed 2-12-97; 8:45 am]  
 BILLING CODE 4140-01-M

### National Library of Medicine; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C., Appendix 2), notice is hereby given of the following National Library of Medicine Special Emphasis Panel (SEP) meeting:

*Name of SEP:* National Library of Medicine Special Emphasis Panel.

*Date:* February 10, 1997.

*Time:* 11:00 a.m.

*Place:* Conference Call, 8600 Rockville Pike, Bldg. 38A, Rm. 5S-522, Bethesda, Maryland 20894, 301/496-4221.

*Contact:* Dr. Roger W. Dahlen, Chief, Biomedical Information Support Branch, EP, 8600 Rockville Pike, Bldg. 38A, Rm. 5S-522, Bethesda, Maryland 20894, 301/496-4221.

*Purpose/Agenda:* To evaluate and review Fellowship grant applications. The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93-879—Medical Library Assistance, National Institutes of Health)

Dated: February 7, 1997.  
 LaVerne Y. Stringfield,  
*Committee Management Officer, NIH.*  
 [FR Doc. 97-3631 Filed 2-10-97; 2:31 pm]  
 BILLING CODE 4140-01-M

### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* March 6-8, 1997.

*Time:* 8:00 a.m.

*Place:* Redlion Inn, Richland, Washington.

*Contact Person:* Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda, Maryland 20892, (301) 435-1180.

*Name of SEP:* Clinical Sciences.

*Date:* March 20, 1997.

*Time:* 8:00 a.m.

*Place:* Holiday Inn, Chevy chase, Maryland.

*Contact Person:* Ms. Josephine Pelham, Scientific Review Administrator, 6701 Rockledge Drive, Room 4106, Bethesda, Maryland 20892, (301) 435-1786.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* March 20, 1997.

*Time:* 3:00 p.m.

*Place:* NIH, Rockledge 2, Room 4144, Telephone Conference.

*Contact Person:* Dr. Paul Strudler, Scientific Review Administrator, 6701 Rockledge Drive, Room 4144, Bethesda, Maryland 20892, (301) 435-1716.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* March 24-25, 1997.

*Time:* 8:30 a.m.

*Place:* Doubletree Hotel, Rockville, Maryland.

*Contact Person:* Dr. Garrett Keefer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4190, Bethesda, Maryland 20892, (301) 435-1152.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* April 14-16, 1997.

*Time:* 4:00 p.m.

*Place:* Hampton Inn, Urbana, Illinois.

*Contact Person:* Dr. Nancy Lamontagne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4170, Bethesda, Maryland 20892, (301) 435-1726.

*Name of SEP:* Clinical Sciences.

*Date:* April 18, 1997.

*Time:* 11:00 a.m.

*Place:* NIH, Rockledge 2, Room 4126, Telephone Conference.

*Contact Person:* Dr. Jerrold Fried, Scientific Review Administrator, 6701 Rockledge Drive, Room 4126, Bethesda, Maryland 20892, (301) 435-1777.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 39.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.392, 93.893, National Institutes of Health, HHS)

Dated: February 7, 1997.

LaVerne Y. Stringfield,

*Committee Management Officer, NIH.*

[FR Doc. 97-3633 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

### **Prospective Grant of Exclusive License: Diagnostic Test for Alzheimer's Disease**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to NeuroLogic, Inc. of Washington, D.C. The patents and patent applications to be licensed are U.S. Patent No. 5,580,748 issued December 3, 1996 (U.S. Patent Application Serial No. 08/056,456 filed May 3, 1993), entitled "Cell Test for Alzheimer's Disease," and all continuation applications, divisional applications, continuation-in-part applications, and foreign counterpart applications related to U.S. Patent Application Serial No. 08/056,456.

**SUPPLEMENTARY INFORMATION:** The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Alzheimer's disease (AD) represents the fourth leading cause of death in the United States, killing over 100,000 annually, and afflicting some 4 million Americans and is projected to affect

over 14 million by the year 2050. Various reports indicate that the incidence of Alzheimer's disease increases with age and estimate that the prevalence of AD in people over 80 years of age is between 20 and 50%. Under currently available technology AD can only be positively diagnosed by pathological examination of brain tissue during autopsy in conjunction with a clinical history of dementia.

Present efforts to diagnosis the disease have been generally directed to the identification and detection of molecules present in blood samples or in cerebral spinal fluid (CSF). Current tests for the detection of Alzheimer's disease have met with varying degrees of commercial success. The proposed technology involves the identification of Alzheimer's disease utilizing fibroblast cells. The method consists of: Measuring the presence or absence of a specific potassium channel, measuring the effect of potassium channel blockers specific for the 113 pS potassium channel on intracellular calcium levels, measuring the increase of intracellular calcium in response to an activator of intracellular calcium release in the cells of a patient, and measuring the amount of the G-protein, cp20.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: Stephen L. Finley, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852; Telephone: (301) 496-7056, ext. 215; Facsimile: (301) 492-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 14, 1997, will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 4, 1997.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 97-3530 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

### **Substance Abuse and Mental Health Services Administration**

#### **Office for Women's Services; Notice of Meeting**

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Advisory Committee for Women's Services of the Substance Abuse and Mental Health Services Administration (SAMHSA) in February 1997.

The meeting of the Advisory Committee for Women's Services will include a discussion of policy and program issues relating to women's substance abuse and mental health service needs; the SAMHSA fiscal year 1998 budget; resolutions adopted at the Committee's September meeting; consideration of September meeting minutes; and other policy issues.

A summary of the meeting and/or a roster of committee members may be obtained from: Pamela J. McDonnell, Executive Secretary, Advisory Committee for Women's Services, Office for Women's Services, SAMHSA, Parklawn Building, Room 13-99, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443-5184.

Substantive information may be obtained from the contact whose name and telephone number is listed below.

*Committee Name:* Advisory Committee for Women's Services.

*Meeting Date(s):* February 24, 1997.

*Place:* Room 12-94, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

*Open:* February 24, 2:00 p.m. to 4:00 p.m.

*Contact:* Pamela J. McDonnell, Room 13-99, Parklawn Building, Telephone: (301) 443-5184.

This notice is being published less than 15 days prior to the meeting due to the urgent need to resolve pending issues before a full meeting can be scheduled.

Dated: February 7, 1997.

Jeri Lipov,

*Committee Management Officer, Substance Abuse and Mental Health Services Administration.*

[FR Doc. 97-3586 Filed 2-12-97; 8:45 am]

BILLING CODE 4162-20-P

### **DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT**

[Docket No. FR-4200-N-24]

#### **Notice of Proposed Information Collection for Public Comment**

**AGENCY:** Office of the Assistant Secretary for Policy Development and Research, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below